Telomir back in compliance with Nasdaq rule

Telomir Pharmaceuticals, Inc. reported that on March 30, 2026 it received a letter from the Nasdaq Capital Markets confirming the company is now in compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported that on March 30, 2026 it received a letter from the Nasdaq Capital Markets confirming the company is now in compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders. Nasdaq has determined the matter is closed, meaning Telomir’s listing status related to this meeting requirement is no longer in question.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Nasdaq rule: Rule 5620(a) Nasdaq compliance confirmation date: March 30, 2026 Annual meeting referenced: 2025 Annual Meeting of Shareholders

3 metrics

Nasdaq rule Rule 5620(a) Listing rule Telomir is now in compliance with

Nasdaq compliance confirmation date March 30, 2026 Date Nasdaq letter confirmed compliance

Annual meeting referenced 2025 Annual Meeting of Shareholders Meeting after which compliance was confirmed

Key Terms

Nasdaq Listing Rule 5620(a), Emerging growth company, Annual Meeting of Shareholders

3 terms

Nasdaq Listing Rule 5620(a) regulatory

"the Company is now in compliance with Nasdaq Listing Rule 5620(a)"

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Annual Meeting of Shareholders financial

"upon holding its 2025 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Telomir Pharmaceuticals (TELO) announce in this 8-K filing?

Telomir Pharmaceuticals announced it received confirmation from Nasdaq that it is back in compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders, and Nasdaq has deemed the related compliance matter closed.

Why is Nasdaq Listing Rule 5620(a) important for Telomir Pharmaceuticals (TELO)?

Nasdaq Listing Rule 5620(a) requires listed companies to hold an annual meeting of shareholders. Telomir’s confirmation of compliance means it has satisfied this corporate governance requirement, removing a specific Nasdaq listing concern tied to its 2025 Annual Meeting of Shareholders.

What event brought Telomir Pharmaceuticals (TELO) back into Nasdaq compliance?

Holding its 2025 Annual Meeting of Shareholders brought Telomir Pharmaceuticals back into compliance with Nasdaq Listing Rule 5620(a). After this meeting, Nasdaq notified the company that the prior issue regarding this rule is resolved and the matter is considered closed.

When did Telomir Pharmaceuticals (TELO) receive Nasdaq’s compliance letter?

Telomir Pharmaceuticals received Nasdaq’s compliance letter on March 30, 2026. The letter confirmed that, following the company’s 2025 Annual Meeting of Shareholders, it now complies with Nasdaq Listing Rule 5620(a), and Nasdaq considers the compliance matter closed.

Does Telomir Pharmaceuticals’ 8-K mention any changes to its Nasdaq listing status?

The filing states that Nasdaq informed Telomir Pharmaceuticals the company is now in compliance with Nasdaq Listing Rule 5620(a) and has determined the compliance matter closed. This indicates the specific listing concern related to that rule has been resolved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/31/2026 - 09:15 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2026

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida

001-41952

87-2606031

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 30, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) received a letter from the Nasdaq Capital Markets informing the Company that upon holding its 2025 Annual Meeting of Shareholders, the Company is now in compliance with Nasdaq Listing Rule 5620(a) and has determined the matter now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.

Dated: March 31, 2026	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents